Jen­nifer Zi­olkows­ki re­signs from CFO post at Sol­id Bio­sciences; Sean Bo­hen's Ole­ma On­col­o­gy adds San­dra Horn­ing to board of di­rec­tors

Jen­nifer Zi­olkows­ki has de­cid­ed to step down from Ilan Gan­ot’s team at Sol­id Bio­sciences “to pur­sue a new ca­reer op­por­tu­ni­ty,” ac­cord­ing to an SEC doc­u­ment filed Fri­day. Zi­olkows­ki will con­tin­ue to be Sol­id’s CFO un­til Jan. 29, 2021. The day af­ter she an­nounced her res­ig­na­tion at the com­pa­ny, the Duchenne mus­cu­lar dy­s­tro­phy biotech en­tered in­to a con­sult­ing agree­ment with Dan­forth Ad­vi­sors, at which point Dan­forth man­ag­ing part­ner Stephen Di­Pal­ma was named in­ter­im CFO. Di­Pal­ma has been a CFO be­fore at Fo­rum Phar­ma­ceu­ti­cals and Aquila Bio­phar­ma­ceu­ti­cals, and he found­ed Cat­a­lyst On­col­o­gy and Athena Di­ag­nos­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.